Relmada appoints Julie Chen as Director of Finance and Operations

2 October 2014

US pain therapeutic specialists Relmada Therapeutics (OTCQB: RLMD) has appointed Julie Chen as its Director of Finance and Operations.

Ms Chen brings almost 20 years' business experience and financial analysis to Relmada. Most recently, she has been a consultant with Credo Partners where her responsibilities have included analyzing financial models, conducting due diligence and participating in the business strategy discussions. She has also conducted data analysis, reviews of companies' operations and internal controls and collected proprietary market and industry intelligence to assist with action oriented recommendations.

Sergio Traversa, Relmada chief executive, said: "We are very pleased to have Julie joining the Relmada team in the capacity of Director of Finance and Operations. She brings project management, financial and procedural know-how to the job. With her technical background in addition to her financial analytical training, she is well-positioned for success with us."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical